###begin article-title 0
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Association between novel TARDBP mutations and Chinese patients with amyotrophic lateral sclerosis
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 188 195 188 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
TARDBP mutations have been reported in patients with amyotrophic lateral sclerosis (ALS) in different populations except Chinese. The present aim is to investigate the association between TARDBP mutations and Chinese patients with ALS.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1 </italic>
###xml 79 86 79 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
71 SALS patients and 5 FALS families with non-SOD1 mutations were screened for TARDBP mutations via direct sequencing.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 125 133 <span type="species:ncbi:9606">children</span>
###xml 146 153 <span type="species:ncbi:9606">patient</span>
###xml 188 195 <span type="species:ncbi:9606">patient</span>
A novel heterozygous variation, Ser292Asn (875G>A), was identified in the proband and 4 asymptomatic relatives including the children of the dead patient from a FALS family. Thus the dead patient, the proband's brother, was speculated to carry Ser292Asn though his sample was unavailable to the detection. This variation was not found in 200 unrelated control subjects. A homology search of the TDP-43 protein in different species demonstrated that it was highly conserved. Also, it was predicted to be deleterious to protein function with SIFT-calculated probabilities of 0.00. Therefore, Ser292Asn is predicted to be a pathogenic mutation. In addition, we have found two silent mutations (Gly40Gly and Ala366Ala) and one novel polymorphism (239-18t>c).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 144 152 <span type="species:ncbi:9606">patients</span>
The present data have extended the spectrum of TARDBP mutations and polymorphisms, and supported the pathological role of TDP-43 in Chinese ALS patients.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 558 562 558 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 631 635 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SETX</italic>
###xml 654 660 654 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DCTIN1</italic>
###xml 675 678 675 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANG</italic>
###xml 726 730 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAPB</italic>
###xml 760 763 760 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS</italic>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 811 812 811 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 889 890 889 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1140 1147 1140 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 1250 1251 1250 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1252 1253 1252 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1279 1286 1279 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 1332 1333 1332 1333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1334 1336 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1592 1599 1592 1599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
###xml 880 887 <span type="species:ncbi:9606">patient</span>
###xml 1322 1330 <span type="species:ncbi:9606">patients</span>
###xml 1620 1628 <span type="species:ncbi:9606">patients</span>
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by progressive loss of upper and lower motor neurons from the spinal cord, brain stem and cerebral cortex, leading to paralysis and eventually death which is due to respiratory failure within 3-5 years after symptom onset [1]. Approximately 5-10% of ALS cases are familial (FALS) whereas the remaining patients are sporadic (SALS) [2]. About 15-20% of patients with autosomal dominant FALS have mutations in the copper-zinc superoxide dismutase 1 gene (SOD1), while mutations in other genes including alsin (ALS2), senataxin (SETX, ALS4), dynactin (DCTIN1), angiogenin (ANG), synaptobrevin-associated membrane protein B (VAPB, ALS8) and Fused in Sarcoma (FUS, ALS6) are described as rare causes of FALS [2-5]. Recently, a novel senataxin mutation has been reported in a SALS patient [6]. Ubiquitin-positive tau-negative neuronal cytoplasmic inclusion is the common pathological feature in frontotemporal lobar degeneration (FTLD) and ALS. TAR DNA-binding protein 43 (TDP-43), which is a 414-amino-amino-acid nuclear protein encoded by TARDBP on chromosome 1p36.22, was recognized as a major constituent of these neuronal cytoplasmic inclusions [7,8]. To date, a total of 30 TARDBP mutations have been reported in ALS patients [9-20]. These mutations affect the C-terminal region of TDP-43 and may influence protein-protein interaction, exon skipping and splicing inhibitory activity, thus, may influence the proper function or transport of TDP-43. Here, we first reported the screen for TARDBP mutations in Chinese patients with ALS and we identified one novel missense mutation, two silent mutations and one novel polymorphism.
###end p 10
###begin title 11
Methods
###end title 11
###begin title 12
Subjects
###end title 12
###begin p 13
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1 </italic>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 632 638 <span type="species:ncbi:9606">person</span>
###xml 698 706 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 838 846 <span type="species:ncbi:9606">patients</span>
###xml 954 957 <span type="species:ncbi:9606">men</span>
###xml 966 971 <span type="species:ncbi:9606">women</span>
###xml 1055 1061 <span type="species:ncbi:9606">people</span>
###xml 1181 1193 <span type="species:ncbi:9606">participants</span>
Seventy-one unrelated SALS patients and probands from 5 FALS families with non-SOD1 mutations from the Han ethnic group were enrolled in our study between 12 December 2007 and 3 March 2009 from department of Neurology at Huashan Hospital. Of them, 56 were males and 20 were females, and the average age of symptom onset was 52 years (range, 32-76 years). All patients had been examined by at least two neurologists. Neurological examinations including electromyography (EMG) and magnetic resonance imaging (MRI) of the cervical cord were performed. Medical history and demographic information were collected by a specially-assigned person, and records were reviewed by two senior neurologists. All patients were diagnosed as definite ALS according to the Airlie House criteria [21]. 16 patients presented with bulbar-onset disease and 60 patients presented with spinal-onset disease. Two hundred unrelated aged individuals (>/=60 years) consisted of 100 men and 100 women with no known history of ALS were selected as a control group. All of them are Han people from Southern China. This study was approved by the local ethics committee, and informed consent was obtained from the participants or their legal surrogates prior to inclusion in the study. Genomic DNA was extracted from peripheral EDTA blood with a TIANamp Blood DNA kit (TIANGEN Biotech, Beijing).
###end p 13
###begin title 14
Mutation scanning
###end title 14
###begin p 15
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 573 580 573 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 689 696 689 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
The coding region of TARDBP, exons 2-6, including the intron-exon boundaries, were analyzed using primer combinations designed based on the intronic sequences of TARDBP. PCR amplification was performed using a GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA, USA) with standard conditions. The sequence of the primers and the annealing temperatures are shown in the Table 1. Amplified products were purified and subjected to direct sequencing, and the procedure is as previously reported [22]. Obtained sequences were compared with the genomic DNA sequence of TARDBP (NCBI Sequence Viewer NT_021937.18), and nucleotide changes were numbered corresponding to their position in TARDBP mRNA (NCBI Sequence Viewer NM_007375.3).
###end p 15
###begin p 16
###xml 25 32 25 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
Primers designed for the TARDBP gene and conditions of PCR
###end p 16
###begin title 17
Results
###end title 17
###begin title 18
Mutations and polymorphisms of TARDBP gene identified in the present study
###end title 18
###begin p 19
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 185 192 <span type="species:ncbi:9606">patient</span>
After screening mutations of TARDBP in 5 FALS patients and 71 SALS patients, a heterozygous variation Ser292Asn (875G>A) which has not been reported previously was identified in a FALS patient. The chromatogram is shown in figure 1A. This variation was not found in 200 unrelated control subjects, reducing the likelihood that it represents a polymorphism. Moreover, a homology search of the TDP-43 protein in different species demonstrated that this variation was highly conserved (figure 1B). At the same time, the program SIFT (Sorting Intolerant From Tolerant) [23] has been applied to predict whether this sequence change could affect protein function, and it was predicted to be deleterious to protein function with SIFT-calculated probabilities of 0.00, thus Ser292Asn is a novel mutation and most probably a pathogenic one.
###end p 19
###begin p 20
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Chromatogram of Ser292Asn (A) and conservation of Ser292Asn in different species (B)</bold>
Chromatogram of Ser292Asn (A) and conservation of Ser292Asn in different species (B).
###end p 20
###begin p 21
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 166 173 <span type="species:ncbi:9606">patient</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 369 376 <span type="species:ncbi:9606">patient</span>
###xml 519 526 <span type="species:ncbi:9606">patient</span>
In addition, two silent mutations, Gly40Gly (120G>A) and Ala366Ala (1098C>G) were detected. The Gly40Gly which has not been reported previously was found in one SALS patient and none of 200 unrelated control individuals, indicating that it is a rare silent mutation. The Ala366Ala which has been previously reported in Japanese SALS patients [20] was found in one SALS patient and one control individual, thus it was thought to be a benign polymorphism. We also have detected a novel polymorphism 239-18t>c in one SALS patient and one control individual. The chromatograms of them are shown in additional file 1.
###end p 21
###begin title 22
###xml 30 37 <span type="species:ncbi:9606">patient</span>
Clinical features of the FALS patient carrying Ser292Asn mutation
###end title 22
###begin p 23
###xml 76 77 76 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 65 72 <span type="species:ncbi:9606">patient</span>
###xml 1481 1488 <span type="species:ncbi:9606">patient</span>
The Ser292Asn mutation was identified in a 67-year-old male FALS patient (II2). He had some difficulty in speech at the age of 64 and gradually presented dysarthria, dysphagia and atrophy of lingual muscle. One year later, he began to have some difficulty in using chopsticks and lifting his right arm, and gradually developed weakness of both upper limbs and atrophy of muscles. However, the fasciculation was slight. After another 4 months, he began to feel weakness in both lower extremities and started having difficulties in walking up and down stairs. Neurological examination showed muscle weakness involving all the extremities with motor power graded as follows: upper limbs, 3/4; lower limbs, 4/5. However, the sensation was intact. Atrophy of lingual muscle and distal muscles of upper limbs were evident. There was positive Babinski sign, and the deep-tendon reflexes were increased in both lower limbs whereas decreased in both upper limbs. EMG testing showed reduced amplitudes of compound muscle-action potentials in right median nerve, positive sharp waves, fibrillations, and normal motor and sensory NCV. He was treated with coenzyme Q10 60 mg daily and followed with follow-up examinations every three months. At the last follow-up 2 months ago, neurological examination showed progression of disease. The powers of upper limbs were both 2/3 grades and powers of lower limbs were both 3/4 grades. Dysarthria and dysphagia were more and more evident, whereas the patient refused Bi-level positive airway pressure (BiPAP) and percutaneous endoscopic gastrostomy (PEG).
###end p 23
###begin title 24
Pedigree analysis of the ALS family with Ser292Asn mutation
###end title 24
###begin p 25
###xml 47 48 47 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
The pedigree of this family is shown in figure 2. The proband's younger brother (II5) developed right lower limb weakness at the age of 58, and gradually extended to muscles of both lower limbs and upper limbs. Two years later, he developed bulbar symptoms and died of respiratory failure at the age of 61.
###end p 25
###begin p 26
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The pedigree with Ser292Asn</bold>
The pedigree with Ser292Asn. "*" indicates the asymptomatic relatives carrying Ser292Asn.
###end p 26
###begin p 27
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 103 104 103 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 108 110 108 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9 </sub>
###xml 116 118 116 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">13</sub>
###xml 136 138 136 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sub>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 176 177 176 177 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 182 183 182 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 194 196 194 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sub>
###xml 215 216 215 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 221 222 221 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 227 228 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 317 319 317 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7 </sub>
###xml 344 345 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 350 352 350 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7 </sub>
###xml 359 361 359 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8 </sub>
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 538 540 538 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6 </sub>
###xml 547 549 547 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7 </sub>
###xml 589 590 589 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 618 620 618 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 </sub>
###xml 151 159 <span type="species:ncbi:9606">children</span>
###xml 557 565 <span type="species:ncbi:9606">children</span>
###xml 578 585 <span type="species:ncbi:9606">patient</span>
###xml 587 590 <span type="species:ncbi:9606">II5</span>
###xml 616 619 <span type="species:ncbi:9606">II5</span>
Direct sequencing was performed to screen for Ser292Asn in the proband's mother (I2), three sisters (II7, II9 and II13), one brother (II11), and their children (III3, III5, III6, III7, III8, III11). Four of them (II7, III6, III7, III8) were detected to have Ser292Asn. They haven't any clinical symptoms presently. II7 is 60 years old while III6, III7 and III8 are less than 40 years old. Because the 85-year-old mother (I2) doesn't have Ser292Asn, we speculated that Ser292Asn might be come from the dead father who was asymptomatic. III6 and III7 are the children of the dead patient (II5), thus we speculate that II5 carried the Ser292Asn mutation, although his sample is unavailable for confirmation.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 317 352 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The TDP-43, which is a 414-amino-amino-acid nuclear protein encoded by TARDBP on chromosome 1p36.22, has been identified as the major disease protein in ALS. It is evolutionary conserved and its structure consists of a glycine-rich domain and two RNA recognition motifs [24]. It is known to bind DNA and RNA, such as human immunodeficiency virus type 1 TAR DNA sequence motifs [25], and to be involved in the regulation of messenger RNA splicing and exon skipping [26]. The importance of the glycine-rich C-terminal domain of TDP-43 in mediating its exon skipping and splicing inhibitory ability has been demonstrated and has been observed to correlate with its ability to interact with other members of the heterogeneous nuclear ribonuclear A and B protein families with well-known splicing inhibitory properties [27]. However, the exact function remains unclear.
###end p 29
###begin p 30
###xml 30 37 30 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 724 731 724 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 857 864 857 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 940 947 940 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 1024 1031 1024 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 1159 1161 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 922 930 <span type="species:ncbi:9606">patients</span>
Recently different pathogenic TARDBP mutations have been described in different cohorts of patients with FALS and SALS, supporting a direct role of TDP-43 in neurodegeneration [9-20]. However, two additional studies by Gijselinck I et al and Guerreiro RJ et al failed to find mutations in Belgian and North American patients with ALS [28,29]. Among the 30 previously reported mutations [9-20], 29 are missense mutations, and one is frameshift mutation (Tyr374Term) which creates a premature stop codon, consequently leading to the expression of a truncated protein [17]. None of them is homozygous. Met337Val, Gly348Cys and Ala382Thr are the most common mutations. Additionally, except for the Asp169Gly mutation, all other TARDBP mutations are located in exon 6 encoding for the C-terminus of TDP-43. Considering all the previous studies, the frequency of TARDBP mutations is 3.6% in FALS and 1.0% in SALS [16]. Most ALS patients carrying TARDBP mutations have an Italian or French origin, suggesting a higher frequency of TARDBP mutations in Southern Europe (average 3.4%; 8% in France and 2.7% in Italy) than in other Caucasian populations (average 0.7%) [16].
###end p 30
###begin p 31
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
###xml 631 633 631 633 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 639 641 639 641 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 </sub>
###xml 823 824 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 829 830 829 830 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 835 836 835 836 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sub>
###xml 841 842 841 842 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sub>
###xml 921 922 921 922 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 927 929 927 929 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7 </sub>
###xml 936 938 936 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8 </sub>
###xml 1014 1016 1014 1016 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7 </sub>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 335 343 <span type="species:ncbi:9606">patients</span>
###xml 637 640 <span type="species:ncbi:9606">II5</span>
In the present study, after screening TARDBP mutations in 71 unrelated SALS patients and probands from 5 FALS families in Chinese population, we have identified one missense mutation in a FALS family and 2 silent mutations in SALS patients. This frequency is lower than those of previous studies, which may be due to the cohort of ALS patients analyzed here is small compared to previous studies. Also, different races may refer to different genetic backgrounds. The Ser292Asn mutation was located in the highly conserved region, exon6, encoding for the C-terminus of TDP-43. In the FALS family with Ser292Asn, we speculated that I1 and II5 might both carry Ser292Asn though their samples are unavailable to the detection. The proband presented clinical symptoms at the age of 64. However, the other four family members (II7, III6, III7, III8) carried the same mutation as the proband did were asymptomatic presently. III6, III7 and III8 are in their thirties and obviously haven't reached the onset age of ALS. II7 is 60 years old though she is clinically asymptomatic. We suggest detecting EMG examination to her but she refused.
###end p 31
###begin title 32
Conclusion
###end title 32
###begin p 33
###xml 54 61 54 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP </italic>
In conclusion, our data have extended the spectrum of TARDBP mutations and polymorphisms, and supported the pathological role of TDP-43 in ALS. Further studies are needed to shed light on the pathophysiological link between Ser292Asn and ALS. Competing interestsThe authors declare that they have no competing interests.
###end p 33
###begin title 34
Authors' contributions
###end title 34
###begin p 35
###xml 0 15 0 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hui-Ling Xiong </bold>
###xml 127 141 127 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Jin-Yang Wang </bold>
###xml 145 156 145 156 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Yi-Min Sun </bold>
###xml 277 299 277 299 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Jian-Jun Wu, Yan Chen </bold>
###xml 303 312 303 312 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kai Qiao </bold>
###xml 356 370 356 370 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gui-xian Zhao </bold>
###xml 374 390 374 390 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Qiao-Juan Zheng </bold>
###xml 431 443 431 443 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Zhi-Ying Wu </bold>
###xml 4 8 <span type="species:ncbi:163112">Ling</span>
Hui-Ling Xiong carried out the molecular genetic studies, participated in the analysis of the data and drafted the manuscript. Jin-Yang Wang and Yi-Min Sun collected demographic data and risk factor profiles of subjects and participated in analysis and interpretation of data. Jian-Jun Wu, Yan Chen and Kai Qiao analyzed the clinical data of all subjects. Gui-xian Zhao and Qiao-Juan Zheng participated in the acquisition of data. Zhi-Ying Wu conceived of the study, and participated in its design and coordination, and revising the manuscript critically for important intellectual content. All authors have read and approved the final manuscript.
###end p 35
###begin title 36
Pre-publication history
###end title 36
###begin p 37
The pre-publication history for this paper can be accessed here:
###end p 37
###begin p 38

###end p 38
###begin title 39
Supplementary Material
###end title 39
###begin title 40
Additional file 1
###end title 40
###begin p 41
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Chromatograms of silent mutations (Gly40Gly and Ala366Ala) and the novel polymorphism (239-18t&gt;c). </bold>
Chromatograms of silent mutations (Gly40Gly and Ala366Ala) and the novel polymorphism (239-18t>c). The normal sequence is shown in the upper half and the corresponding mutation is shown below.
###end p 41
###begin p 42
Click here for file
###end p 42
###begin title 43
Acknowledgements
###end title 43
###begin p 44
###xml 27 35 <span type="species:ncbi:9606">patients</span>
We sincerely thank the ALS patients and their family members. The authors also thank the reviewers for improving the manuscript. This work was supported by grant from Huashan Hospital for special professorship of Fudan University, Shanghai, and grant FMU-RT002 of program for Innovative Research Team in Science and Technology in the Fujian Province University and grant JS6037 from Fujian Medical College for professorship, Fuzhou, China.
###end p 44
###begin article-title 45
From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS
###end article-title 45
###begin article-title 46
Molecular biology of amyotrophic lateral sclerosis: insights from genetics
###end article-title 46
###begin article-title 47
Genetics of familial and sporadic amyotrophic lateral sclerosis
###end article-title 47
###begin article-title 48
Genetics of familial amyotrophic lateral sclerosis
###end article-title 48
###begin article-title 49
Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6
###end article-title 49
###begin article-title 50
###xml 63 70 <span type="species:ncbi:9606">patient</span>
A novel mutation in the senataxin gene identified in a Chinese patient with sporadic amyotrophic lateral sclerosis
###end article-title 50
###begin article-title 51
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 51
###begin article-title 52
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations
###end article-title 52
###begin article-title 53
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis
###end article-title 53
###begin article-title 54
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
###end article-title 54
###begin article-title 55
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis
###end article-title 55
###begin article-title 56
TDP-43 A315T mutation in familial motor neuron disease
###end article-title 56
###begin article-title 57
TDP-43 mutation in familial amyotrophic lateral sclerosis
###end article-title 57
###begin article-title 58
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations
###end article-title 58
###begin article-title 59
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis
###end article-title 59
###begin article-title 60
###xml 51 59 <span type="species:ncbi:9606">patients</span>
High frequency of TARDBP gene mutations in Italian patients with amyotrophic lateral sclerosis
###end article-title 60
###begin article-title 61
Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis
###end article-title 61
###begin article-title 62
TDP-43 M311V mutation in familial amyotrophic lateral sclerosis
###end article-title 62
###begin article-title 63
###xml 37 45 <span type="species:ncbi:9606">patients</span>
TARDBP (TDP-43) sequence analysis in patients with familial and sporadic ALS: identification of two novel mutations
###end article-title 63
###begin article-title 64
Screening for TARDBP mutations in Japanese familial amyotrophic lateral sclerosis
###end article-title 64
###begin article-title 65
World Federation of Neurology Research Group on Motor Neuron Diseases. EI Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
###end article-title 65
###begin article-title 66
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Mutation analysis of 218 Chinese patients with Wilson disease revealed no correlation between the canine copper toxicosis gene MURR1 and Wilson disease
###end article-title 66
###begin article-title 67
SIFT: predicting amino acid changes that affect protein function
###end article-title 67
###begin article-title 68
Structural diversity and functional implications of the eukaryotic TDP gene family
###end article-title 68
###begin article-title 69
###xml 80 115 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs
###end article-title 69
###begin article-title 70
TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing
###end article-title 70
###begin article-title 71
###xml 70 75 <span type="species:ncbi:9606">human</span>
Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease
###end article-title 71
###begin article-title 72
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS
###end article-title 72
###begin article-title 73
TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis
###end article-title 73

